---
title: "Nitazoxanide Targets Mitochondria to Reduce Liver Metastases in Uveal Melanoma Models"
id: "pubmed-43059405"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43059405"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43059405/"
doi: "10.3892/mmr.2026.14070"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nitazoxanide Targets Mitochondria to Reduce Liver Metastases in Uveal Melanoma Models
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43059405
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43059405/)
- **DOI:** [10.3892/mmr.2026.14070](https://doi.org/10.3892%2Fmmr.2026.14070)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study evaluated **nitazoxanide** (NTZ) for antitumor activity against **uveal melanoma** (UM) using two UM cell lines (Mel270, Mel290) and an intrasplenic mouse xenograft model. - In vitro, investigators reported mitochondrial uncoupling after NTZ exposure, with reduced mitochondrial membrane potential and lower oxygen consumption rate in UM cells. - NTZ decreased cell viability, impaired colony formation and limited cellular proliferation in culture models; the cohort showed cell‑cycle arrest at G0–G1. - The study team observed reduced cell migration after NTZ treatment, indicating an antimetastatic cellular phenotype in vitro. - Mechanistic data indicated acute NTZ exposure stimulated phosphorylation of **AMPK**, while downregulating **mTOR** signaling and acetyl‑CoA carboxylase pathways. - In male NOD‑SCID‑γ mice receiving intrasplenic UM cell injections, oral NTZ reduced the incidence of hepatic metastasis compared with controls. - Data indicated a functional reliance on mitochondrial oxidative phosphorylation in these UM models; authors noted NTZ‑targeted mitochondrial function as a therapeutic axis. - The abstract did not report detailed dosing regimens, pharmacokinetics, toxicity measures, or human clinical data; the source did not provide these specifics. - The findings derive from cell culture and an immunodeficient mouse xenograft model; translation to patients remains unaddressed in the source material.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43059405/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43059405%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43059405/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43059405/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43059405/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43059405/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43059405/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43059405%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43059405%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43059405/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43059405/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43059405/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43059405/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43059405/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43059405/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43059405/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43059405/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43059405/#substances) Title & authors Abstract MeSH terms Substances Mol Med Rep Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Med+Rep%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Med+Rep%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) . 2027 Jan;35(1):12. doi: 10.3892/mmr.2026.14070. Epub 2026 Nov 20. # Anticancer efficacy of nitazoxanide for targeting liver metastasis of uveal melanoma by disrupting the cancer bioenergetic profile [Amer Alasadi](https://pubmed.ncbi.nlm.nih.gov/?term=Alasadi+A&cauthor_id=43059405)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#full-view-affiliation-1 "Department of Medical Basic Science, College of Nursing, University of Thi‑Qar, Thi‑Qar 00964, Iraq."), [Noor Fadhil](https://pubmed.ncbi.nlm.nih.gov/?term=Fadhil+N&cauthor_id=43059405)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#full-view-affiliation-2 "Department of Nutrition Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA."), [Husam Al-Hraishawi](https://pubmed.ncbi.nlm.nih.gov/?term=Al-Hraishawi+H&cauthor_id=43059405)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#full-view-affiliation-3 "Department of Physiology, College of Medicine, Misan University, Misan 00964, Iraq.") Affiliations Expand ### Affiliations * 1 Department of Medical Basic Science, College of Nursing, University of Thi‑Qar, Thi‑Qar 00964, Iraq. * 2 Department of Nutrition Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA. * 3 Department of Physiology, College of Medicine, Misan University, Misan 00964, Iraq. * PMID: **43059405** * DOI: [ 10.3892/mmr.2026.14070 ](https://doi.org/10.3892/mmr.2026.14070) Item in Clipboard # Anticancer efficacy of nitazoxanide for targeting liver metastasis of uveal melanoma by disrupting the cancer bioenergetic profile Amer Alasadi et al. Mol Med Rep. 2027 Jan. Show details Display options Display options Format Abstract PubMed PMID Mol Med Rep Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Med+Rep%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Med+Rep%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) . 2027 Jan;35(1):12. doi: 10.3892/mmr.2026.14070. Epub 2026 Nov 20. ### Authors [Amer Alasadi](https://pubmed.ncbi.nlm.nih.gov/?term=Alasadi+A&cauthor_id=43059405)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#short-view-affiliation-1 "Department of Medical Basic Science, College of Nursing, University of Thi‑Qar, Thi‑Qar 00964, Iraq."), [Noor Fadhil](https://pubmed.ncbi.nlm.nih.gov/?term=Fadhil+N&cauthor_id=43059405)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#short-view-affiliation-2 "Department of Nutrition Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA."), [Husam Al-Hraishawi](https://pubmed.ncbi.nlm.nih.gov/?term=Al-Hraishawi+H&cauthor_id=43059405)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43059405/#short-view-affiliation-3 "Department of Physiology, College of Medicine, Misan University, Misan 00964, Iraq.") ### Affiliations * 1 Department of Medical Basic Science, College of Nursing, University of Thi‑Qar, Thi‑Qar 00964, Iraq. * 2 Department of Nutrition Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA. * 3 Department of Physiology, College of Medicine, Misan University, Misan 00964, Iraq. * PMID: **43059405** * DOI: [ 10.3892/mmr.2026.14070 ](https://doi.org/10.3892/mmr.2026.14070) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Uveal melanoma (UM) is the most common intraocular malignancy affecting adults. It originates from melanocytes within the ocular tract mainly in the choroid and to a lesser extent in the iris and ciliary body. The incidence of UM varies according to geographical location and ethnicity. Patient mortality is associated with the development of metastasis to the liver, and despite the limited control of the primary cancer and its major therapeutic dilemmas, metabolic needs of cancer have been revealed as a druggable strategy for the treatment of UM. The present study aimed to investigate the anticancer and antimetastatic effects of nitazoxanide (NTZ) using UM (Mel270 and Mel290) cell lines to assess cell viability, cell cycle, and cellular responses through western blot analysis together with a mouse model established by intrasplenic injection to evaluate liver metastasis and tumor incidence. NTZ uncouples the mitochondria by reducing the membrane potential and oxygen consumption rate in UM cancer cells. NTZ treatment in UM cells was demonstrated to notably inhibit cell growth, proliferation and the colony development in cell culture models. Moreover, NTZ halted the cell cycle at G0‑G1 stage, reducing cell migration of UM cancer cells. Mechanistically, acute treatment of UM cells with NTZ stimulated adenosine monophosphate‑activated serine/threonine protein kinase phosphorylation and downregulated mTOR and the acetyl‑CoA carboxylase signaling pathway. Furthermore, oral treatment of NTZ reduced the hepatic metastasis when UM cells were transplanted intrasplenically in male non‑obese diabetic‑severe combined immunodeficient‑γ mouse model. Overall, the findings of the current study reveal the notable role for mitochondrial oxidative phosphorylation in UM and highlight NTZ‑targeted mitochondrial function as a new therapeutic area to treat the liver metastasis of human UM. **Keywords:** glycolysis; hepatic metastasis; nitazoxanide; uveal melanoma. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Antineoplastic Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Cell Cycle / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Cycle%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Cycle) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Cell Movement / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Movement%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Movement) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Cell Proliferation / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Proliferation%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Proliferation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Cell Survival / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Survival%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Survival) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Energy Metabolism* / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Energy+Metabolism%2Fdrug+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Energy+Metabolism) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Liver Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Liver+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Liver Neoplasms* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver+Neoplasms%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Liver+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Liver Neoplasms* / secondary Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver+Neoplasms%2Fsecondary%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Liver+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Male Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Male) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Melanoma* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Melanoma* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Melanoma* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Mice Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mice%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mice) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Mitochondria / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mitochondria%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mitochondria) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Mitochondria / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mitochondria%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mitochondria) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Nitro Compounds / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nitro+Compounds%2Fpharmacology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Nitro+Compounds) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Thiazoles* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Thiazoles%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Thiazoles) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Uveal Melanoma Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Uveal+Melanoma%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Uveal+Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Uveal Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Uveal+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Uveal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Uveal Neoplasms* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Uveal+Neoplasms%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Uveal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Uveal Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Uveal+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Uveal+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) * Xenograft Model Antitumor Assays Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Xenograft+Model+Antitumor+Assays%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Xenograft+Model+Antitumor+Assays) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43059405/) ## Substances * Nitro Compounds Actions * [ Search in PubMed ](https://
## Related Clinical Research

- [UV-related Tumor Mutational Burden Predicts Melanoma Mortality in Stage II/III InterMEL Cohort](https://medichelpline.com/clinical-feed/medrxiv-11-uv-induced-mutations-are-associated-with-melanoma-specific-mortality-in-stage.md)
- [Continuous karyotypic instability and structural flux in acral melanoma genomes](https://medichelpline.com/clinical-feed/biorxiv-0-continuous-karyotypic-and-cryptic-structural-fluctuations-drive-acral-melanoma.md)
- [Cancer vaccines and neoantigen strategies in the immunotherapy era](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-cancer-vaccines-in-the-era-of-immunotherapy-from-antigen-delivery-to-immune.md)
- [VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers](https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of.md)
- [Trends in childhood, teenage and young adult cancer incidence in England, 2001–2020](https://medichelpline.com/clinical-feed/pubmed-42833137.md) (DOI: 10.1016/j.ejca.2026.117448)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.